We are live on ! Find out more
RSCM

Rock Springs Capital Management Portfolio holdings

AUM $1.7B
1-Year Est. Return 93.03%
This Fund
S&P 500
This Quarter Est. Return
+8.6%
1 Year Est. Return
+93.03%
3 Year Est. Return
+228.43%
5 Year Est. Return
+368.14%
10 Year Est. Return
+4,607.77%
AUM
$1.35B
AUM Growth
+$157M
Cap. Flow
+$100M
Cap. Flow %
7.42%
Top 10 Hldgs %
27.65%
Holding
142
New
12
Increased
63
Reduced
5
Closed
5

Top Buys

Rank Stock Value
1
SHPG
Shire pic
SHPG
+$21.7M
2
CI icon
Cigna
CI
+$11.2M
3
GWPH
GW Pharmaceuticals Plc American Depositary Shares
GWPH
+$10.4M
4
CLSD
Clearside Biomedical
CLSD
+$9.46M
5
HOLX
Hologic
HOLX
+$7.96M

Top Sells

Rank Stock Value
1
BXLT
BAXALTA INC COM STK (DE)
BXLT
+$32.7M
2
ELV icon
Elevance Health
ELV
+$16.8M
3
ANAC
ANACOR PHARMACEUTICALS INC COM
ANAC
+$9.49M
4
COO icon
Cooper Companies
COO
+$7.33M
5
INOV
Inovalon Holdings, Inc. Class A Common Stock
INOV
+$5.78M

Sector Composition

Rank Sector Weight
1 Healthcare 77.95%
2 Financials 3.98%
3 Industrials 0.47%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
NVDQ
76
DELISTED
Novadaq Technologies Inc.
NVDQ
$5.46M 0.4%
555,000
– –
AVXS
77
DELISTED
AveXis, Inc. Common Stock
AVXS
$5.43M 0.4%
142,758
– –
CGEN icon
78
Compugen
CGEN
$228M
$5.31M 0.39%
820,000
– –
CO
79
DELISTED
Global Cord Blood Corporation
CO
$5.06M 0.37%
880,000
– –
KA
80
DELISTED
Kineta, Inc. Common Stock
KA
$5.03M 0.37%
2,964
-393
-12% -$716K
INSM icon
81
Insmed
INSM
$28.6B
$4.91M 0.36%
497,500
+47,500
+11% +$554K
INSY
82
DELISTED
Insys Therapeutics, Inc.
INSY
$4.73M 0.35%
365,500
– –
KDNY
83
DELISTED
Chinook Therapeutics, Inc. Common Stock
KDNY
$4.69M 0.35%
83,000
– –
ALDR
84
DELISTED
Alder Biopharmaceuticals
ALDR
$4.51M 0.33%
180,500
+83,000
+85% +$2.25M
TNDM icon
85
Tandem Diabetes Care
TNDM
$1.56B
$4.49M 0.33%
59,500
+3,250
+6% +$262K
XENT
86
DELISTED
Intersect ENT, Inc
XENT
$4.4M 0.33%
340,000
– –
AGN.PRA
87
DELISTED
Allergan plc
AGN.PRA
$4.16M 0.31%
5,000
– –
PTLA
88
DELISTED
Portola Pharmaceuticals, Inc.
PTLA
$4.13M 0.31%
175,000
– –
KITE
89
DELISTED
Kite Pharma, Inc.
KITE
$4M 0.3%
80,000
– –
ASND icon
90
Ascendis Pharma A/S
ASND
$16.8B
$3.98M 0.29%
300,000
+30,000
+11% +$462K
RIGL icon
91
Rigel Pharmaceuticals
RIGL
$750M
$3.9M 0.29%
175,000
+28,595
+20% +$711K
OTIC
92
DELISTED
Otonomy, Inc.
OTIC
$3.81M 0.28%
240,000
– –
FOLD
93
DELISTED
Amicus Therapeutics
FOLD
$3.71M 0.27%
680,000
+66,500
+11% +$465K
KYNB
94
Kyntra Bio
KYNB
$29.4M
$3.69M 0.27%
9,000
+840
+10% +$385K
CYTO
95
DELISTED
Altamira Therapeutics Ltd
CYTO
$3.56M 0.26%
11
+1
+10% +$299K
INVA icon
96
Innoviva
INVA
$1.48B
$3.55M 0.26%
+336,900
New +$3.99M
GI
97
DELISTED
EndoChoice Holdings, Inc.
GI
$3.48M 0.26%
710,000
+120,000
+20% +$572K
PRGO icon
98
Perrigo
PRGO
$1.78B
$3.44M 0.25%
37,900
+7,900
+26% +$818K
TSRO
99
CALL
DELISTED
TESARO, Inc.
TSRO
$3.36M 0.25%
+40,000
New +$1.78M
NBRV
100
DELISTED
Nabriva Therapeutics plc Ordinary Shares Ireland
NBRV
$3.19M 0.24%
1,704
+184
+12% +$371K
2 3
4
5 6

Similar funds

ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
BCM
BlueCrest Capital Management St Helier, Jersey $1.69B AUM 20.01% 1-Year Est. Return
PP
PDT Partners New York $1.69B AUM 74.01% 1-Year Est. Return
GAM
Goldentree Asset Management New York $1.69B AUM 10.69% 1-Year Est. Return
FACM
Forest Avenue Capital Management Miami, Florida $1.69B AUM 104.84% 1-Year Est. Return
RMC
Ribbit Management Company Palo Alto, California $1.68B AUM 40.61% 1-Year Est. Return
JIP
Jaffetilchin Investment Partners Tampa, Florida $1.68B AUM 22.81% 1-Year Est. Return
II
Inspire Investing Meridian, Idaho $1.71B AUM 31.76% 1-Year Est. Return

Rock Springs Capital Management's Q2 2016 Portfolio in Review

As of Q2 2016, Rock Springs Capital Management held 142 positions worth $1.35B, up 13% from $1.19B the previous quarter. Its ten largest holdings account for 28% of the portfolio.

Rock Springs Capital Management deployed $100M of net new capital in Q2 2016, opening 12 new positions and adding to 63 existing holdings. Its largest new stake was Shire pic: 120,042 shares worth $22.1M.

By sector, the portfolio is most concentrated in Healthcare at 78% of assets, up from 78% a quarter earlier, followed by Financials and Industrials.

On the sell side, the largest reduction was Inovalon Holdings, Inc. Class A Common Stock, an estimated $5.78M trimmed.

  • Rock Springs Capital Management's largest Q2 2016 buy was Shire pic: 120,042 shares worth $22.1M.
  • Rock Springs Capital Management added most to Cigna in Q2 2016, an estimated $11.2M increase.
  • Rock Springs Capital Management's biggest Q2 2016 reduction was Inovalon Holdings, Inc. Class A Common Stock, cutting an estimated $5.78M.
  • Rock Springs Capital Management fully exited BAXALTA INC COM STK (DE) in Q2 2016, selling an estimated $32.7M.
  • Rock Springs Capital Management's ten largest holdings make up 28% of its $1.35B portfolio in Q2 2016.
  • Rock Springs Capital Management opened 12 new positions and closed 5 in Q2 2016.
  • Rock Springs Capital Management's portfolio value rose 13% quarter-over-quarter to $1.35B.

Based on Rock Springs Capital Management's 13F filing for Q2 2016, filed 15 Aug 2016.